SPY330.57-3.94 -1.18%
DIA277.00-1.90 -0.68%
IXIC10,720.36-189.92 -1.74%

Raymond James Upgrades CymaBay Therapeutics to Outperform, Announces $7 Price Target

Raymond James analyst Steven Seedhouse upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Market Perform to Outperform and announces $7 price target.

Benzinga · 05/12/2020 10:21

Raymond James analyst Steven Seedhouse upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Market Perform to Outperform and announces $7 price target.